thalidomide has been researched along with (pPNET) Peripheral Primitive Neuroectodermal Tumors in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Q | 1 |
| Liu, Y | 1 |
| Yu, Y | 1 |
1 review available for thalidomide and (pPNET) Peripheral Primitive Neuroectodermal Tumors
| Article | Year |
|---|---|
Antiangiogenic therapy for primitive neuroectodermal tumor with thalidomide: A case report and review of literature.
Topics: Adolescent; Angiogenesis Inhibitors; Biopsy, Needle; Bronchoscopy; Follow-Up Studies; Humans; Immuno | 2017 |